Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness and safety of lanadelumab (DazeYou) and ecallantide (FeiZeYou) in hereditary angioedema patients in China
CTR20241912Phase 4Completed
- Sponsor
- Dyax Corp.
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of ecallantide in hereditary angioedema (HAE), sponsored by Dyax Corp.. Started Jun 2024; status: completed.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20241912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241912.